SequelSEC

Lexaria Bioscience Corp. LEXX

Pharmaceutical Preparations · CIK 0001348362 · Fiscal year ends 0831

AnnualQuarterlyTTM
Revenue
$194.00K
Fiscal year ended 2026-05-31
Operating income
-$7.71M
Fiscal year ended 2026-05-31
Free cash flow
-$7.47M
Fiscal year ended 2026-05-31

Valuation, from the filing

Public float$24.60MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-02-28
Float per share$1.11Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue34.8×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity9.5×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-02-28, not today, and each multiple below it uses the figures for the fiscal year ending 2025-08-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Gross margin99.6%97th
FCF margin-1483.9%20th
R&D / revenue1167.1%76th
Revenue YoY growth52.0%76th
Net margin-1686.0%26th
Operating margin-1683.0%26th
SBC / revenue121.8%70th
Current ratio2.32x31th
CapEx / revenue3.5%62th

Lexaria Bioscience Corp. (LEXX) reported revenue of $194.00K and net income of -$7.73M for the fiscal year ended 2026-05-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Lexaria Bioscience Corp.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Lexaria Bioscience Corp. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-05-31
Revenue$194.00K
Cost of revenue$0
Gross profit$194.00K
Operating income-$7.71M
Net income-$7.73M
Research & development$4.00M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$3.90M
Selling & marketingUnavailable

Balance

Lexaria Bioscience Corp. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-05-31
Cash & equivalents$3.50M
Total assets$4.78M
Current assets$4.06M
Total liabilities$437.09K
Current liabilities$383.41K
Total equity incl. NCI$4.34M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$49.00K
GoodwillUnavailable
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

Lexaria Bioscience Corp. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-05-31
Operating cash flow-$7.43M
Capital expenditures$40.82K
Investing cash flow-$243.98K
Financing cash flow$6.52M
Net change in cash-$1.12M
Stock-based compensation$365.46K
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$57.23K

Derived

Lexaria Bioscience Corp. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-05-31
Free cash flow-$7.47M
Gross margin100.0%
Operating margin-3973.2%
FCF margin-3848.6%
SBC / revenue188.4%
Current ratio10.60x
Revenue YoY growth-68.5%
Net margin-3985.6%
R&D / revenue2061.7%
CapEx / revenue21.0%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open LEXX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-13View SEC filing
10-Q · Filed 2026-04-13View SEC filing
10-Q · Filed 2026-01-13View SEC filing
10-K · Filed 2025-11-28View SEC filing
10-Q · Filed 2025-07-14View SEC filing
10-Q · Filed 2025-04-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.